Compare abrdn Income Credit Strategies Fund (ACP) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
abrdn Income Credit Strategies Fund vs Medpace Holdings Inc — how do they compare? abrdn Income Credit Strategies Fund trades at $5.21 (market cap $656.21M), while Medpace Holdings Inc trades at $529.18 (market cap $15.60B). The key difference: Medpace Holdings Inc is far larger — about 23.8× abrdn Income Credit Strategies Fund's market cap, and abrdn Income Credit Strategies Fund pays a 17.78% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals.
| ACP | MEDP | |
|---|---|---|
Market Cap | $656.21M | $15.60B |
Sector | Financials | Technology |
52-Week High | $5.98 | $620.59 |
52-Week Low | $5.01 | $308.88 |
Dividend Yield | 17.78% | — |
Enterprise Value | — | $15.07B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACP trades at $5.25, down 0.57% today, with a neutral technical signal. The stock shows a low P/B of 0.89 and a high net income margin of 95.51% for 2024, though revenue declined from $79M in 2024 to $42M in 2025. Recent news highlights dividend declarations and a Seeking Alpha downgrade citing distribution sustainability concerns. Cash flow from operations was negative $81.31M in 2024, offset by financing inflows.
Outlook is mixed: valuation appears modest with a P/E near 16, but declining revenue and negative operating cash flow pose risks. The 17% distribution rate faces sustainability questions, while technical indicators suggest limited near-term momentum. Investors should weigh income potential against fundamental weaknesses and high beta exposure.
Medpace (MEDP) trades at $565.09, up 1.34% with a bullish technical outlook supported by moving averages. The company demonstrates strong fundamentals with consistent earnings beats, 17.19% net margins, and robust ROE of 77.25%. Recent news highlights shifting CRO demand dynamics and upcoming Q2 2026 earnings on July 22. The stock trades near 52-week highs with technical indicators showing overbought conditions.
MEDP presents growth potential from steady revenue expansion and strong profitability, though elevated valuations (P/E 35.59) and class action lawsuits pose risks. Analyst consensus leans cautious with 63% hold ratings and $465 price target below current levels. The stock's upside depends on continued earnings outperformance and backlog quality improvement.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About abrdn Income Credit Strategies Fund
abrdn Income Credit Strategies Fund is a diversified, closed-end investment management company. Its primary goal is to generate high current income, with capital appreciation as a secondary objective. The fund mainly invests in debt and loan instruments from issuers across various industries and regions.
Read more on ACP →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
